A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Pfizer

Status and phase: Completed; Phase 2

Conditions: Smoking Cessation

Treatments: Drug: CP-526,555 (varenicline)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00150241

A3051002

Details and patient eligibility

About

The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have smoked on average of at least ten cigarettes per day during the past year
• Subjects must have no period of abstinence greater than three months in the past year

Exclusion criteria

• Subjects with any history of cardiovascular disease
• Myocardial infarction
• Significant arrhythmias
• Poorly controlled hypertension

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind